中国科学院大连化学物理研究所机构知识库
Advanced  
DICP OpenIR  > 中国科学院大连化学物理研究所  > 期刊论文
题名: psi-Bufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling
作者: Ding, Jin1;  Wen, Wen1;  Xiang, Daimin1;  Yin, Peipei1, 2;  Liu, Yanfang3;  Liu, Chang2;  He, Guoping1;  Cheng, Zhuo1;  Yin, Jianpeng5;  Sheng, Chunquan4;  Zhang, Wen4;  Nan, Fajun5;  Ye, Wencai6;  Zhang, Xiuli3;  Wang, Hongyang1, 7
关键词: psi-Bufarenogin ;  hepatocellular carcinoma ;  epithelial growth factor receptor ;  hepatocyte growth factor receptor
刊名: ONCOTARGET
发表日期: 2015-05-10
卷: 6, 期:13, 页:11627-11639
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology ;  Life Sciences & Biomedicine
类目[WOS]: Oncology ;  Cell Biology
研究领域[WOS]: Oncology ;  Cell Biology
英文摘要: Resistance of hepatocellular carcinoma (HCC) to existing chemotherapeutic agents largely contributes to the poor prognosis of patients, and discovery of novel anti-HCC drug is in an urgent need. Herein we report psi-Bufarenogin, a novel active compound that we isolated from the extract of toad skin, exhibited potent therapeutic effect in xenografted human hepatoma without notable side effects. In vitro, psi-Bufarenogin suppressed HCC cells proliferation through impeding cell cycle progression, and it facilitated cell apoptosis by downregulating Mcl-1 expression. Moreover,psi-Bufarenogin decreased the number of hepatoma stem cells through Sox2 depression and exhibited synergistic effect with conventional chemotherapeutics. Mechanistic study revealed that psi-Bufarenogin impaired the activation of MEK/ERK pathway, which is essential in the proliferation of hepatoma cells. psi-Bufarenogin notably suppressed PI3-K/Akt cascade, which was required in psi-Bufarenogin-mediated reduction of Mcl-1 and Sox2. psi-Bufarenogin inhibited the auto-phosphorylation and activation of epithelial growth factor receptor (EGFR) and hepatocyte growth factor receptor (c-Met), thereafter suppressed their primary downstream cascades Raf/MEK/ERK and PI3-K/Akt signaling. Taken together, psi-Bufarenogin suppressed HCC growth via inhibiting, at least partially, receptor tyrosine kinases-regulated signaling, suggesting that psi-Bufarenogin could be a novel lead compound for anti-HCC drug.
关键词[WOS]: ADVANCED HEPATOCELLULAR-CARCINOMA ;  CELL LUNG-CANCER ;  STEM-CELLS ;  INTERACTION CHROMATOGRAPHY ;  APOPTOSIS ;  MET ;  BUFADIENOLIDES ;  IDENTIFICATION ;  PROLIFERATION ;  ACTIVATION
语种: 英语
WOS记录号: WOS:000359006400073
Citation statistics: 
内容类型: 期刊论文
URI标识: http://cas-ir.dicp.ac.cn/handle/321008/146429
Appears in Collections:中国科学院大连化学物理研究所_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Second Mil Med Univ, Int Cooperat Lab Signal Transduct, Eastern Hepatobiliary Surg Hosp, Shanghai, Peoples R China
2.Shanghai Inst Pharmaceut Ind, Dept Pharmacol, Shanghai, Peoples R China
3.Chinese Acad Sci, Dalian Inst Chem Phys, Key Lab Separat Sci Analyt Chem, Dalian, Peoples R China
4.Second Mil Med Univ, Coll Pharm, Shanghai, Peoples R China
5.Natl Ctr Drug Screen, Shanghai, Peoples R China
6.Jinan Univ, Coll Pharm, Guangzhou, Guangdong, Peoples R China
7.Natl Ctr Liver Canc, Shanghai, Peoples R China

Recommended Citation:
Ding, Jin,Wen, Wen,Xiang, Daimin,et al. psi-Bufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling[J]. ONCOTARGET,2015,6(13):11627-11639.
Service
 Recommend this item
 Sava as my favorate item
 Show this item's statistics
 Export Endnote File
Google Scholar
 Similar articles in Google Scholar
 [Ding, Jin]'s Articles
 [Wen, Wen]'s Articles
 [Xiang, Daimin]'s Articles
CSDL cross search
 Similar articles in CSDL Cross Search
 [Ding, Jin]‘s Articles
 [Wen, Wen]‘s Articles
 [Xiang, Daimin]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
  Add to CiteULike  Add to Connotea  Add to Del.icio.us  Add to Digg  Add to Reddit 
所有评论 (0)
暂无评论
 
评注功能仅针对注册用户开放,请您登录
您对该条目有什么异议,请填写以下表单,管理员会尽快联系您。
内 容:
Email:  *
单位:
验证码:   刷新
您在IR的使用过程中有什么好的想法或者建议可以反馈给我们。
标 题:
 *
内 容:
Email:  *
验证码:   刷新

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Powered by CSpace